Sign in

    Matthew Vinita • AGP

    No available evidence suggests that Matthew Vinita is an analyst or holds any position at AGP, nor do there appear to be any relevant records or profiles matching that query among analyst databases, LinkedIn searches, or professional news. There is no found track record of company coverage, investment performance, or professional licensing information for this individual in the context specified. As a result, a comprehensive professional profile cannot be produced based on the criteria requested.

    Matthew Vinita's questions to INmune Bio Inc (INMB) leadership

    Matthew Vinita's questions to INmune Bio Inc (INMB) leadership • Q3 2024

    Question

    Matthew Vinita, on for Jim Molloy, requested more details on the R&D rebate from Australia, including how the funds can be used and its potential impact on reducing future cash burn.

    Answer

    CFO David Moss clarified that the rebate is an unrestricted cash-back incentive for conducting R&D in Australia, with funds being reinvested into clinical programs. The recent rebate was tied to the ADO2 trial. He conservatively estimated a future rebate of around $4 million for the next year, which will help reduce the company's burn rate.

    Ask Fintool Equity Research AI